Buy Erlonat/Erlotinib 150mg tablets with price | Myapplepharma

1. Myapplepharma Erlonat 150mg tablet |  Erlotinib 150mg tablets

2. Erlonat tablets consist of active ingredients known as Erlotinib (Generic Tarceva), that is considered as quinazoline derivative and anti-cancer agents that responses as a protein kinase prohibitors for EGFR related to tyrosine kinase. Erlonat is majorly used in the treatment of non-small cell lung cancer and pancreatic carcinoma and also involved to treat various cancers.  Erlonat 150mg is especially aimed the epidermal growth factor receptor tyrosine kinase. Erlonat 150mg tablet (Erlotinib)

3. Erlonat is indicated as continuance therapy, in patients with long lasting or metastasis non small cell lung carcinoma, whose disease has not get advance after four cycles with platinum based first line therapy Erlonatis used in this condition only after the failure of one prior chemotherapy regimen.  Erlonat 150mg with platinum based compounds like Carboplatin, gemcitabine or cisplatin.  USES OF Erlonat

4. Erlonat has pharmacological effects like anti-neoplastic activity, which exhibits its action by inhibiting the intracellular phosphorylation of tyrosine kinase related with epidermal growth factor receptor. This EGFR is present on the surface of the tumor cells. Thus results as inhibition causes interfere with signal transduction and lead to cell lyses. ErlonatWORKS

5. The peak plasma concentration time reaches at 4 hours after drug intake After an oral administration of Erlonat, causes 60% of oral bioavailability. Increased by meals to 100%. Smoking should be avoided during the treatment with Erlonat 150mg, causes decreasing the exposure of Erlotinib. The apparent volume of distribution of Erlotinib is 232L Human protein binding to Erlotinib is occurs as 93%.  Erlotinib metabolites occurs via; Feces: 83%; urine: 8% half life period of Erlotinib is 36.2 hours. PHARMACOKINETICS

6. Pulmonary toxicity: Interstitial lung disease and other pulmonary toxicity conditions, Avoid the treatment with Erlonat Renal failure: Frequent monitoring of renal function or serum electrolytes occurs or avoids the treatment  Hepatic function should be periodically monitored, or otherwise discontinue the therapy with Erlonat. WARNING AND PRECAUTIONS

7. Co administration of Erlonat with midazolam causes decreasing the AUC of CYP3A4 substrate. Drugs involved in alteration of pH levels causes variation in solubility of Erlotinib. Avoid concomitant use of gastric regulators with Erlonat. Erlonat concomitant with statins drugs (lipid lowering drug), causes increasing the concentration of these drugs (rosuvastatin, simvastatin or atorvastatin). CYP3A4 strong inhibitors like itraconazole, grape fruit juice, rotonavir, indinaviretc CYP3A4 inducers concurrently used with Erlonat tablets causes decreasing the exposure of Erlotinib.  SOME INTERACTION WITH SOME OTHER DRUGS

8. In Erlonat 150mgtherapy, no contraindication occurs. In some patients hypersensitivity reactions present due to patients are contraindicated to the ingredients in Erlonat. In case of missed dose, patients must consult with medical oncologist and follow the regular dosing schedule. CONTRAINDICATION

9. some undesirable effects like; Paronychia, Bullous, blistering and expoliative skin conditions like Stevens Johnson’s syndrome. Gastrointestinal perforation Hepatic failure occurs during monotherapy or combination with other chemotherapy agents  Some common side effects: Diarrhea, Fatigue, Anorexia, Pruritus, Acne, Dermatitis, Dry skin, Loss of weight, Paronychia, Cough, Vomiting, Conjunctivitis, Keratoconjuctivitiessicca, Abdominal pain, Stomatits, Infection, nausea, Bone pain, Alopecia, Anxiety, Neuropathy, Renal disorders, hepatic disorders, ocular disorders, skin, hair and nail disorders. SIDE EFFECTS

10. phone No      :9987711567 Email             :info@myapplepharma.com website          https://myapplepharma.com/erlonat-150mg.php Contact Us